Literature DB >> 17537651

Rho activation is required for transforming growth factor-beta-induced epithelial-mesenchymal transition in lens epithelial cells.

Hee Jun Cho1, Jiyun Yoo.   

Abstract

Lens epithelial cells undergo epithelial-mesenchymal transition (EMT) after injury as in cataract extraction, leading to fibrosis of the lens capsule. We have recently shown that TGF-beta-induced EMT in lens epithelial cells depends on PI3 kinase/Akt signal pathway. In this report, we suggest Smad3 is necessary for TGF-beta-induced EMT by showing that the expression of dominant-negative Smad3 blocks the expression of alpha-smooth muscle actin (alpha-SMA) and morphological changes. We also show that TGF-beta induces a biphasic change in Rho activity, and that Y27632, a selective inhibitor of Rho effector ROCK, inhibits TGF-beta-induced EMT in vitro and in vivo. We finally show that Smad3 activation and Rho signal activation is independent each other. All of these findings suggest that Rho/ROCK activation together with Smad3 is necessary for TGF-beta-induced EMT in lens epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537651     DOI: 10.1016/j.cellbi.2007.04.006

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  33 in total

Review 1.  Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Rik Derynck
Journal:  Cells Tissues Organs       Date:  2010-11-02       Impact factor: 2.481

2.  Rho activation is apically restricted by Arhgap1 in neural crest cells and drives epithelial-to-mesenchymal transition.

Authors:  Matthew R Clay; Mary C Halloran
Journal:  Development       Date:  2013-06-26       Impact factor: 6.868

3.  Adenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3.

Authors:  Miguel Perez-Aso; Patricia Fernandez; Aránzazu Mediero; Edwin S Chan; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-11-07       Impact factor: 5.191

4.  ROCK Inhibition Extends Passage of Pluripotent Stem Cell-Derived Retinal Pigmented Epithelium.

Authors:  Roxanne H Croze; David E Buchholz; Monte J Radeke; William J Thi; Qirui Hu; Peter J Coffey; Dennis O Clegg
Journal:  Stem Cells Transl Med       Date:  2014-07-28       Impact factor: 6.940

Review 5.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

6.  Effect of C3 transferase on human adipose-derived stem cells.

Authors:  Natsuko Kakudo; Satoshi Kushida; Kenji Suzuki; Nagisa Matsumoto; Kenji Kusumoto
Journal:  Hum Cell       Date:  2011-10-09       Impact factor: 4.174

7.  Matrix metalloproteinase-9-null mice are resistant to TGF-β-induced anterior subcapsular cataract formation.

Authors:  Anna Korol; Giuseppe Pino; Dhruva Dwivedi; Jennifer V Robertson; Paula A Deschamps; Judith A West-Mays
Journal:  Am J Pathol       Date:  2014-05-06       Impact factor: 4.307

8.  In vitro inhibition of proliferation, migration and epithelial-mesenchymal transition of human lens epithelial cells by fasudil.

Authors:  Jing-Zhi Shao; Ying Qi; Shan-Shan Du; Wen-Wen Du; Fu-Zhen Li; Feng-Yan Zhang
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

9.  Suppression of injury-induced epithelial-mesenchymal transition in a mouse lens epithelium lacking tenascin-C.

Authors:  Sai-ichi Tanaka; Takayoshi Sumioka; Norihito Fujita; Ai Kitano; Yuka Okada; Osamu Yamanaka; Kathleen C Flanders; Masayasu Miyajima; Shizuya Saika
Journal:  Mol Vis       Date:  2010-07-01       Impact factor: 2.367

10.  The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma.

Authors:  Miao-Fen Chen; Kuan-Der Lee; Ming-Shian Lu; Chih-Cheng Chen; Ming-Ju Hsieh; Yun-Hen Liu; Paul-Yang Lin; Wen-Cheng Chen
Journal:  J Mol Med (Berl)       Date:  2008-12-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.